107
Participants
Start Date
August 28, 2015
Primary Completion Date
April 26, 2018
Study Completion Date
February 7, 2020
Imetelstat 4.7 mg/kg
Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
Imetelstat 9.4 mg/kg
Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
Birmingham
Duarte
La Jolla
Los Angeles
Stanford
Washington D.C.
Tampa
West Palm Beach
Chicago
Louisville
Baltimore
Ann Arbor
Rochester
St Louis
Buffalo
Lake Success
New York
The Bronx
Charlotte
Durham
Winston-Salem
Cincinnati
Philadelphia
Greenville
Watertown
Nashville
Dallas
Seattle
Milwaukee
Antwerp
Bruges
Brussels
Leuven
Edmonton
Winnipeg
Montreal
Angers
Lille
Marseille
Paris
Pierre-Bénite
Toulouse
Aachen
Cologne
Dresden
Düsseldorf
Frankfurt
Hamburg
Heidelberg
Leipzig
Mannheim
Rostock
Haifa
Jerusalem
Kfar Saba
Nahariya
Ramat Gan
Tel Aviv
Bergamo
Bologna
Seoul
Barcelona
Las Palmas de Gran Canaria
Madrid
Salamanca
Valencia
Chiayi City
Taipei
Birmingham
Glasgow
London
Oxford
Lead Sponsor
Geron Corporation
INDUSTRY